Levothyroxine 50 micrograms daily started before conception,
does it really help with Increased live birth in euthyroid women positive for thyroid peroxidase antibodies?
research showsThe grade is D. Live birth at 34 weeks or later occurred in 176/470 women (37.4%) with levothyroxine and 178/470 (37.9%) with placebo: RR 0.97 (95% CI 0.83-1.14), absolute difference -0.4 points (95% CI -6.6 to +5.8), P=.74. The average result showed no benefit, but the interval did not exclude every small benefit.
ads claimThyroid-antibody positivity alone did not establish a live-birth benefit from routine levothyroxine in euthyroid women. Individual TSH values and actual hypothyroidism remain separate clinical decisions.
Useful facts when choosing a product
- Thyroid-antibody testing and levothyroxine prescribing are real decisions in infertility and recurrent-miscarriage care.
- Verdict 923 is A with 86 points for replacement in overt primary hypothyroidism, while verdict 1779 is F with 8 points for fatigue and symptoms in subclinical hypothyroidism. This verdict asks about live birth in euthyroid antibody-positive women.
- A fixed 50-microgram dose began before conception and continued until pregnancy ended.
What the research actually shows
This double-blind placebo-controlled trial at 49 UK hospitals randomized 952 women and obtained the primary outcome in 940. Serious adverse events occurred in 5.9% versus 3.8%, an absolute difference of +2.1 points, P=.14, which was not statistically significant. Funding came from the MRC and NIHR Efficacy and Mechanism Evaluation program. Axis 6 B0 evidence ① Allocation concealment: "Randomisation was conducted through a secure online randomisation service provided by the University of Birmingham Clinical Trials Unit (BCTU)." ② Blinding: "Participants, investigators, research midwives/nurses and other attending clinicians all remained blind to the trial drug allocation for the duration of the trial." ③ Analysis population and missing data: "In the first instance, participants were analysed in the treatment group to which they were randomised, irrespective of compliance with the treatment protocol." Also, "A sensitivity analysis was performed on the primary outcome ... to test the impact of any missing data." ④ Prespecified primary outcome: "The primary outcome was the proportion of women who had a live birth at or beyond 34 completed weeks of gestation." - consistent with ISRCTN15948785 · NCT02130167
Why this is classified as D (34)
A large publicly funded double-blind trial was null for the hard live-birth endpoint, but the interval retained benefit up to 5.8 points, giving D with 34 points.
Counterpoint. Null does not mean that every small benefit was conclusively excluded. The confidence interval does not support that stronger statement.
Rejudgment record. Cross-check applied — A null hard live-birth endpoint in a large publicly funded double-blind trial with benefit up to 5.8 points remaining possible
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased live birth at or beyond 34 weeks | D | The absolute difference was -0.4 points with a 95% CI from -6.6 to +5.8. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | 49-center double-blind placebo-controlled randomized trial | 1 | MRC and NIHR Efficacy and Mechanism Evaluation program | Live birth at or beyond 34 weeks after conception within the post-randomization follow-up | 176/470 (37.4%) versus 178/470 (37.9%), RR 0.97 (95% CI 0.83-1.14), absolute difference -0.4 points (95% CI -6.6 to +5.8), P=.74 | Pivotal large hard-outcome evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Preconception Levothyroxine for Live Birth in Euthyroid Women with Thyroid Antibodies — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/preconception-levothyroxine-euthyroid-thyroid-antibodies-live-birth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.